1. Introduction {#s0005}
===============

Hepatocellular carcinoma (HCC) is a global health problem and causes a huge economic burden for both patients and society. It ranks as the sixth most common cancer in the world, with the highest incidence in China ([@bb0160]). The major environmental risk factors for HCC include chronic hepatitis B and C infection ([@bb0205]). Recent genome-wide association studies have suggested that genetic factors also play an important role in the development of HCC ([@bb0075], [@bb0215]). However, the specific genetic factors contributing to HCC have still remained largely unknown ([@bb0075]).

MicroRNAs (miRNAs) are a family of noncoding small RNAs with 21- to 25-nucleotides, which primarily target the 3′ untranslated regions of targeting messenger RNAs (mRNAs), thus resulting in gene silencing or abnormal expression ([@bb0245]). miRNAs have been predicted to regulate 30% of the human genome, including genes in inflammation, proliferation and apoptosis pathways ([@bb0095]). miRNAs\' deregulation have been shown to be responsible for initiation and progression of HCC ([@bb0210]). A mutation or single nucleotide polymorphism (SNP) within the gene region of miRNAs could alter miRNA expression and thence affect downstream target genes.

The rs2910164 SNP is located within the stem region of an miR-146a precursor and the C to G mutation results in a change from a U:C to a U:G mismatch, while the C to T mutation of the rs11614913 SNP located within the stem region of an miR-196a-2 precursor leads to a change from a G:C to a G:U mismatch ([@bb0045]). Functional studies have shown that such mismatches for miR-146a ([@bb0070]) and for miR-196a-2 ([@bb0105]) could result in reduced expression of both mature miRNAs. Therefore, several studies ([@bb0105], [@bb0005], [@bb0025], [@bb0085], [@bb0225], [@bb0195]) have investigated the two SNPs and HCC risk. Thus far, however, results have been inconsistent. For example, for rs2910164 (miR-146a), [@bb0195] found that the GG genotype increased the risk for HCC, while [@bb0225] did not identify any significant association with HCC. For rs11614913 (miR-196a-2), [@bb0105] found that the CC genotype increased the risk for HCC, while [@bb0050] failed to replicate the findings. We therefore performed this updated meta-analysis using all available papers published in English and Chinese.

2. Material and methods {#s0010}
=======================

2.1. Literature search {#s0015}
----------------------

We did a comprehensive literature search in PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI) database and Wanfang database up to April 01, 2015 using the following search terms: (miR-146a OR microRNA-146a OR rs2910164 OR miR-196a-2 OR microRNA-196a-2 OR rs11614913) AND (hepatocellular carcinoma OR liver cancer OR HCC). Searches were done without restricting on sample size, publication date, language or type of report. We also reviewed references within retrieved articles. For published papers without the required data, corresponding authors were contacted by email for more information. The meta-analysis met the requirements of the PRISMA 2009 checklist ([@bb0125]).

2.2. Criteria for study selection {#s0020}
---------------------------------

The relevant published papers had to meet all the following criteria in order to be included in the meta-analysis: 1) studies focus on human beings; 2) studies use a case--control design evaluating the association between rs2910164 and/or rs11614913 and HCC development; 3) histopathologically confirmed on HCC diagnosis; and 4) detailed information on the allele and genotype frequencies of rs2910164 and/or rs11614913 required for estimating odds ratio (OR) and 95% confidence interval (CI). The details of included and excluded papers are shown in [Fig. 1](#f0005){ref-type="fig"}.

2.3. Data extraction {#s0025}
--------------------

Two authors (MC and FL) independently reviewed potentially eligible studies. The following information were extracted from each: first author\'s name & other publication data, country wherein the study population was recruited, cohort ethnicity, genotyping method, sources of controls, cases and control numbers, and case & control genotype frequencies. The two authors checked the data extraction results and reached consensus on all the data recorded.

2.4. Statistical analysis {#s0030}
-------------------------

The goodness-of-fit test was used to check the Hardy--Weinberg Equilibrium (HWE) in the control samples of each study (P \< 0.05 was considered as deviating from HWE). ORs and 95% CI were calculated to assess the association between rs2910164, rs11614913 and HCC risk in five different models: allele, homozygous, heterozygote, dominant and recessive models. The significance of pooled ORs was considered as statistically significant by the Z test with P \< 0.05. Cochran\'s Q-test (P~Q~) ([@bb0055]) was used to assess the heterogeneity between studies. The fixed-effect model (Mantel--Haenszel method) ([@bb0115]) was used when P~Q~ \> 0.10; otherwise, a random-effects model (DerSimonian and Laird method) ([@bb0030]) was applied. We also performed subgroup analyses by ethnicity, sources of controls and HWE status to further explore the heterogeneity between studies. Sensitivity analyses were performed by removing each study stepwise to examine the robustness of the results. Begg\'s funnel plot and Egger\'s regression asymmetry test were performed to evaluate publication bias ([@bb0035]). All statistical analyses were done using Stata version 12.0 software (StataCorp, College Station, TX).

3. Results {#s0035}
==========

3.1. Study characteristics {#s0040}
--------------------------

A total of 142 potentially relevant studies were identified. A flowchart of the detail selection and exclusion process is shown in [Fig. 1](#f0005){ref-type="fig"}. From this process, twenty-three articles were included for the meta-analysis, of which, seven papers ([@bb0060], [@bb0100], [@bb0065], [@bb0165], [@bb0185], [@bb0220], [@bb0235]) were identified through the CNKI database and Wanfang database (five papers were from theses that have not been published ([Table 1](#t0005){ref-type="table"})), with others identified through PubMed, EMBASE and the Cochrane Library. There were eleven papers ([@bb0085], [@bb0225], [@bb0060], [@bb0100], [@bb0065], [@bb0185], [@bb0220], [@bb0020], [@bb0090], [@bb0145], [@bb0250]) overlapping with both miR-146a and miR-196a-2, thus resulting in nineteen studies for miR-146a with 7170 cases and 9443 controls ([Table 1](#t0005){ref-type="table"}) and fifteen studies for miR-196a-2 with 6417 cases and 7627 controls ([Table 2](#t0010){ref-type="table"}), respectively. For miR-146a, one study used a Turkish population ([@bb0010]); one study used a Korean population ([@bb0085]); and seventeen studies used a Chinese population ([@bb0025], [@bb0225], [@bb0195], [@bb0060], [@bb0100], [@bb0065], [@bb0165], [@bb0185], [@bb0220], [@bb0235], [@bb0020], [@bb0090], [@bb0145], [@bb0250], [@bb0240], [@bb0150], [@bb0180]). For miR-196a-2, one study used a Turkish population ([@bb0005]); one used a Korean population ([@bb0090]); and thirteen studies used a Chinese population ([@bb0105], [@bb0225], [@bb0050], [@bb0060], [@bb0100], [@bb0065], [@bb0185], [@bb0220], [@bb0020], [@bb0090], [@bb0145], [@bb0250], [@bb0140]).

3.2. Association between miRNA polymorphism and HCC susceptibility {#s0045}
------------------------------------------------------------------

For the miR-146a rs2910164 polymorphism, significantly increased risks for HCC development were observed when all studies were pooled under two models (CG vs CC: OR = 1.11, 95% CI = 1.02--1.21, P = 0.021; and GG + CG vs CC: OR = 1.11, 95% CI = 1.01--1.22, P = 0.035). In the subgroup analyses by ethnicity, a significantly increased risk for HCC was found in the Asian population (GG + CG vs CC: OR = 1.11, 95% CI = 1.00--1.23, P = 0.041). Subgroup analysis by control source showed population-based studies to have a significantly increased risk for HCC (GG vs CC: OR = 1.25, 95% CI = 1.04--1.50, P = 0.02; CG vs CC: OR = 1.14, 95% CI = 1.03--1.25, P = 0.01; and GG + CG vs CC: OR = 1.15, 95% CI = 1.02--1.29, P = 0.017). Subgroup analysis by HWE status showed a significantly increased risk for HCC for studies consistent with HWE (G vs C: OR = 1.10, 95% CI = 1.01--1.19, P = 0.022; CG vs CC: OR = 1.16, 95% CI = 1.08--1.26, P \< 0.001; and GG + CG vs CC: OR = 1.18, 95% CI = 1.08--1.28, P \< 0.001) ([Table 3](#t0015){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}).

For the miR-196a-2 rs11614913 polymorphism, significantly increased risks for HCC development were observed when all studies were pooled under four models (C vs T: OR = 1.14, 95% CI = 1.06--1.23, P = 0.001; CC vs TT: OR = 1.31, 95% CI = 1.12--1.53, P = 0.001; CC + TC vs TT: OR = 1.16, 95% CI = 1.03--1.31, P = 0.018; and CC vs TC + TT: OR = 1.14, 95% CI = 1.00--1.30, P = 0.043). In the subgroup analysis for studies with the Asian population and population-based studies, significantly increased risks for HCC development were consistent between the three models (C vs T, CC vs TT and CC + TC vs TT) ([Table 3](#t0015){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}).

3.3. Heterogeneity analysis {#s0050}
---------------------------

Between-study heterogeneity was tested for all the genetic models using the Q-test. For the miR-146a rs2910164 polymorphism, significant heterogeneity between studies was observed for the models (G vs C: P~h~ = 0.001; GG vs CC: P~h~ = 0.003; GG + CG vs CC: Ph = 0.020; and GG vs CG + CC: P~h~ = 0.047) ([Table 3](#t0015){ref-type="table"}). To investigate the sources of heterogeneity, we first carried out meta-regression analyses. These showed that ethnicity, source of controls, genotyping method, HWE in controls and publication year were not effect modifiers (P \> 0.05, data not shown). We then performed subgroup analyses by ethnicity, source of controls and HWE in controls. However, we still observed significant heterogeneity in the subgroup for the models (G vs C, GG vs CC and GG vs CG + CC). Lastly, we did the Galbraith plot analysis to identify outliers that might be causing the heterogeneity. For model (G vs C), the plot showed four studies --- [@bb0100], [@bb0165]), [@bb0235]) and [@bb0145] --- as the outliers in the overall population (Fig. S1). For model (GG vs CC), the plot showed [@bb0100], [@bb0165] and [@bb0235] as the outliers. For model (GG vs CG + CC), the plot showed [@bb0220] as the outlier (Fig. S1). After excluding these outliers in each model, we did not observe any significant heterogeneity in overall results (G vs C: P~h~ = 0.17; GG vs CC: P~h~ = 0.17; and GG vs CG + CC: P~h~ = 0.24). We also did not observe any significant association for HCC risk between these models.

Regarding the miR-196a-2 rs11614913 polymorphism, it showed significant heterogeneity between studies for all the models (C vs T: P~h~ = 0.009; CC vs TT: P~h~ = 0.006; TC vs TT: P~h~ = 0.006; CC + TC vs TT: P~h~ = 0.005; and CC vs TC + TT: P~h~ = 0.006) ([Table 3](#t0015){ref-type="table"}). Meta-regression analysis revealed that the HWE in controls was the major heterogeneity source (P = 0.026), while ethnicity, source of controls, genotyping method, and publication year were not effect modifiers (P \> 0.05, data not shown). For models (C vs T) and (CC vs TT), Galbraith plot analysis showed [@bb0005] and [@bb0250]as the outliers contributing to the heterogeneity. For models (TC vs TT) and (CC vs TC + TT), the plot showed [@bb0145] and [@bb0100] as outliers. For model (CC + TC vs TT), the plot showed [@bb0005] and [@bb0145] as outliers (Fig. S2). However, after excluding these studies in each model, there still remained some degree of heterogeneity for the following models (C vs T: P~h~ = 0.058; CC vs TT: P~h~ = 0.043; and CC + CT vs TT: P~h~ = 0.082). After excluding the outliers, only the CC vs TC + TT model remained significant as showing a link between this SNP and HCC risk (OR = 1.13, 95% CI = 1.02--1.26, P = 0.018, P~h~ = 0.200). In the subgroup analysis by HWE in controls after excluding the outliers in each model, no heterogeneity was observed (P~h~ \> 0.05) for the group consistent with HWE (P \> 0.05) in controls.

3.4. Sensitivity analyses and assessment of publication bias {#s0055}
------------------------------------------------------------

Sensitivity analyses were performed to evaluate the influence of each study on the pooled ORs by sequentially omitting studies. No individual study significantly altered the significance of the pooled ORs, suggesting that the results of the meta-analysis were not being driven by single data points ([Fig. 4](#f0020){ref-type="fig"}).

Begg\'s funnel plot and Egger\'s linear regression test were performed to evaluate potential publication bias. No evidence of obvious asymmetry for the two SNPs was found based on the shapes of the funnel plots ([Fig. 5](#f0025){ref-type="fig"}). The statistic generated using Egger\'s test (t = − 0.80, P = 0.433 for miR-146a rs2910164 model (GG + CG vs CC); t = 0.03, P = 0.980 for miR-196a-2 rs11614913 model (CC vs TC + TT)) also showed no evidence of publication basis.

4. Discussion {#s0060}
=============

Recent studies have suggested an important role for miRNAs\' function as a tumor suppressor influencing both pro- and anti-proliferative cascades ([@bb0040]). Deregulated miRNA and its associated post-transcriptional gene silencing or gene expression comprise an important part in the pathogenesis of HCC ([@bb0210]). Apart from the role of hepatitis viruses which could alter the expression of miRNA ([@bb0155]), variation within the miRNA genetic code itself may also impact the structure of miRNA and thus its expression. To date, nearly 2000 different miRNAs have been identified in humans and about 2200 SNPs within pre-miRNA regions discovered ([@bb0045]). Of these, the two most studied SNPs are the miR-146a rs2910164 and miR-196a-2 rs11614913. However, results for the two SNPs are still controversial. Therefore, we performed this meta-analysis using all the available studies with the largest sample size (N = 16,613 for miR-146a; N = 14,044 for miR-196a-2) to systematically assess the associations and guide future studies. Our results indicate that both polymorphisms are significantly associated with increased HCC risk. In line with other studies, the miR-146a rs2910164 and miR-196a-2 rs11614913 polymorphisms are associated with increased risk for other cancers like colorectal cancer ([@bb0190]) and gastric cancer ([@bb0130]) in the Asian population. The increased risk estimates found in our analysis are somewhat modest (OR \< 1.6). However, the magnitudes found are consistent with those from traditional GWAS studies, which have found many common variants (MAF \> 5%) with modest effects (OR \< 2) ([@bb0120]), but which collectively account for a substantial proportion of risk for developing complex disease.

Functional studies ([@bb0230]) have revealed that miR-146a expression in hepatoma cells and hepatoma tissues is significantly downregulated compared to related normal tissues; this then correlated with liver cancer metastasis. Further evidence has shown that by restoring miR-146a expression, HCC cell invasion and metastasis were significantly suppressed. This inhibition of cell dysfunction by miR-146a was mediated by miR-146a inhibition of VEGF expression through a dual signal pathway model via beta-catenin and NF-kB. Our results support this role for miR-146a in HCC, showing that for the rs2910164 SNP, CG vs CC and GG + CG vs CC increased risk for HCC. As the C to G change for rs2910164 led to reduced expression of miR-146a, carrying the allele G could result in higher HCC risk. However, in the allele model (G vs C), we did not observe a significant association, potentially due to between-study heterogeneity. When we did the subgroup analysis by HWE status, significant association was observed, although some degree of heterogeneity still existed. When outlier studies in each genetic model were excluded, no significant heterogeneity was found. These outlier studies were mostly of relatively small sample size and thus their exclusion is not a great weakness.

Our results indicated the miR-196a-2 rs11614913 SNP as significantly predictive of HCC under all genetics models. However, caution should be taken when interpreting our results, as high heterogeneity existed in these models. The major heterogeneity source was the HWE status in controls as revealed by meta-regression analysis. Another source of heterogeneity came from outliers. The outliers were predominantly either of a Caucasian population ([@bb0005]) or a study by [@bb0145]. After excluding the outliers in each genetic model, no heterogeneity was found for groups that were consistent with HWE (P \> 0.05) in controls. In line with the functional studies, deregulated miR-196a-2 has been shown to target the downstream genes homobox (HOX) and annexin A1 (ANXA1) ([@bb0015]), which both played an important role in the carcinogenesis and malignant transformation of HCC ([@bb0080]).

Several meta-analyses ([@bb0170], [@bb0200], [@bb0110], [@bb0175], [@bb0135]) have systematically summarized the potential association of the two SNPs with susceptibility to HCC. Compared with these previous results, for miR-146a rs2910164, our results differ from the first meta paper published by [@bb0170], in that they did not observe any significant association between miR-146a and HCC risk under any genetic model. This may be because that study only included five studies, with relatively small sample sizes. This is compared with the latest meta-analysis published by [@bb0135], in which they only found such association in the Dominant model (GG + CG vs CC), but not in the heterozygote model (CG vs CC).

For miR-196a-2 rs11614913, [@bb0200] only showed the polymorphism as a risk for HCC in Caucasians, not in Asians. Later work by [@bb0175] found a risk for HCC by the miR-192a SNP to be present in both Caucasians and Asians. However, the latest meta-analysis by [@bb0135] failed to observe any association for this SNP. Our results using the largest samples so far, found the rs11614913 polymorphism as a significant risk factor for HCC in both Caucasians and Asians. One thing in common for previous meta-analyses is the existence of between-study heterogeneity, which can hinder meta-analysis. Therefore, in our analysis, we thoroughly examined the sources of heterogeneity by doing subgroup analysis, meta-regression and Galbraith plot analysis.

There are some limitations in our meta-analysis. Firstly, despite our efforts, some degree of heterogeneity still existed for miR-196a-2 rs11614913. Therefore, it should be acknowledged that the potential heterogeneity might influence these results. Second, we only examined the polymorphism in Caucasians and Asians, while the role of the two SNPs in other ethnicities remains unknown. Lastly, as we do not have the access to the original data, the results could not be adjusted for any other covariates, such as age, gender, etc.

Our findings may provide guidance for further studies. We propose that further studies should try to focus on the role of these two SNPs in predicting HCC clinical course using a prospective cohort study design. Beyond epidemiological studies, laboratory studies attempting to explore the role of miRNA in cellular dysfunction and aberrant proliferation could not only aid in our understanding of these SNPs\' roles, but potentially improve our understanding neoplasia more generally. Taken together, these epidemiological and other analytical methods could aid in the development of targets for intervention in preventing HCC and moderating its clinical course.

In summary, we performed the largest meta-analysis of miR-146a rs2910164 and miR-196a-2 rs11614913 in predicting HCC. Our results provided strong evidence that SNPs within miR-146a and miR-196a-2 contribute to HCC risk in the Asian population. However, further studies validating the results in this and other ethnicities are essential.
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![Flow chart of the selection of the studies and reasons for exclusion from the meta-analysis.](gr1){#f0005}

![Forest plots of the OR for the association of miR-146a rs2910164 with HCC risk in subgroup analysis by HWE status under A) the heterozygote model (CG vs CC), and B) the dominant model (GG + CG vs CC).](gr2){#f0010}

![Forest plots of the OR for the association of miR-196a-2 rs11614913 with HCC risk in subgroup analysis by source of control under A) the allele model (C vs T), B) homozygous model (CC vs TT), C) dominant model (CC + TC vs TT), and D) recessive model (CC vs TC + TT).](gr3){#f0015}

![Sensitivity analysis of miRNA polymorphism with HCC. A) miR-146a rs2910164 model (GG + CG vs CC), and B) miR-196a-2 rs11614913 model (CC vs TC + TT).](gr4){#f0020}

![Begg\'s funnel plot for publication bias. A) Funnel plot for miR-146a rs2910164 with HCC risk in overall analysis for model (GG + CG vs CC), and B) funnel plot for miR-196a-2 rs11614913 with HCC risk in overall analysis for model (CC vs TC + TT).](gr5){#f0025}

###### 

Characteristics of studies included in the meta-analysis for miR-146a rs2910164.

  Study          Year   Country   Ethnicity   Genotyping method   Source of controls   Journal                    GG1   CG1   CC1   GG0   CG0   CC0   HWE
  -------------- ------ --------- ----------- ------------------- -------------------- -------------------------- ----- ----- ----- ----- ----- ----- ----------
  Xu et al.      2008   China     Asian       PCR-RFLP            PB                   Carcinogenesis             80    241   158   58    249   197   0.119
  Xu             2010   China     Asian       PCR-RFLP            PB                   \[Thesis\]                 86    237   177   87    238   197   0.296
  Akkiz et al.   2011   Turkey    Caucasian   PCR-RFLP            PB                   Gene                       137   75    10    144   67    11    0.384
  Wang           2011   China     Asian       MALDI-TOF           PB                   \[Thesis\]                 212   561   343   272   924   673   0.115
  Zhang et al.   2011   China     Asian       PCR-RFLP            PB                   \[CJPM\]                   156   450   319   291   725   577   0.149
  Kim et al.     2012   Korean    Asian       PCR-RFLP            PB                   Gene                       14    88    57    24    103   74    0.19
  Li             2012   China     Asian       AS-PCR              PB                   \[Thesis\]                 124   302   134   92    288   180   0.196
  Xiang et al.   2012   China     Asian       PCR-RFLP            HB                   Molecular biology report   27    45    28    21    46    33    0.506
  Zhou et al.    2012   China     Asian       PCR-RFLP            HB                   DNA and cell biology       33    86    67    71    254   158   0.056
  Huang et al.   2013   China     Asian       MADLI-TOF           HB                   \[CJOPT\]                  12    58    40    15    41    54    0.122
  Shan et al.    2013   China     Asian       PCR-RFLP            HB                   GMR                        28    62    82    36    71    78    0.009
  Zhang et al.   2013   China     Asian       MADLI-TOF           PB                   APJCP                      163   503   331   156   475   367   0.911
  Chu et al.     2014   China     Asian       PCR-RFLP            HB                   Plos One                   22    82    84    50    146   141   0.23
  Cong et al.    2014   China     Asian       PCR-RFLP            HB                   Tumor Biology              27    85    94    17    84    117   0.723
  Hao            2014   China     Asian       PCR-RFLP            PB                   \[Thesis\]                 23    133   70    30    154   97    0.007
  Kou et al.     2014   China     Asian       PCR-RFLP            HB                   Oncology Letter            25    147   99    56    297   179   \< 0.001
  Qi et al.      2014   China     Asian       HRM                 PB                   BMC cancer                 0     165   149   3     244   159   \< 0.001
  Zhou et al.    2014   China     Asian       PCR-RFLP            HB                   Tumor Biology              40    153   73    30    154   97    0.007
  Zhou           2014   China     Asian       PCR-RFLP            HB                   \[Thesis\]                 26    86    61    14    15    12    0.088

PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism, MALDI-TOF: matrix assisted laser desorption/ionization-time of flight mass spectrometry, AS-PCR: allele specific-polymerase chain reaction, HRM: high resolution melting, PB: population based studies, HB: hospital based studies, \[\]: published in Chinese, \[Thesis\]: thesis published in Chinese, \[CJPM\]: Chinese Journal of preventive medicine, \[CJOPT\]: Chinese Journal of Oncology Prevention and Treatment, GMR: Genetics and Molecular Research, APJCP: Asian Pacific Journal of Cancer Prevention, HWE: Hardy--Weinberg equilibrium in control samples, GG1, CG1 and CC1: genotype frequency in cases, GG0, CG0 and CC0: genotype frequency in controls.

###### 

Characteristics of studies included in the meta-analysis for miR-196a-2 rs11614913.

  Study          Year   Country   Ethnicity   Genotyping   Source of   Journal                      CC1   CT1   TT1   CC0   CT0   TT0   HWE
  -------------- ------ --------- ----------- ------------ ----------- ---------------------------- ----- ----- ----- ----- ----- ----- -------
  Li et al.      2010   China     Asian       PCR-RFLP     HB          Pathology                    78    150   82    42    102   78    0.402
  Qi et al.      2010   China     Asian       PCR-LDR      HB          Human immunology             82    179   100   92    197   102   0.869
  Xu             2010   China     Asian       PCR-RFLP     PB          \[Thesis\]                   115   247   130   100   251   144   0.621
  Akkiz et al.   2011   Turkey    Caucasian   PCR-RFLP     PB          Journal of Viral Hepatitis   77    86    22    58    87    40    0.492
  Zhang et al.   2011   China     Asian       PCR-RFLP     PB          \[CJPM\]                     208   449   277   328   817   477   0.972
  Kim et al.     2012   Korea     Asian       PCR-RFLP     PB          Gene                         34    84    41    45    107   49    0.356
  Li             2012   China     Asian       AS-PCR       PB          \[Thesis\]                   148   194   218   98    246   216   0.057
  Han et al.     2013   China     Asian       PCR-RFLP     HB          Plos One                     227   505   305   220   485   304   0.31
  Huang et al.   2013   China     Asian       MADLI-TOF    HB          \[CJOPT\]                    25    52    32    30    53    26    0.784
  Zhang et al.   2013   China     Asian       MADLI-TOF    PB          APJCP                        214   488   294   165   502   328   0.245
  Chu et al.     2014   China     Asian       PCR-RFLP     HB          Plos one                     41    81    66    70    167   100   0.986
  Hao            2014   China     Asian       PCR-RFLP     PB          \[Thesis\]                   77    126   32    67    160   55    0.022
  Kou et al.     2014   China     Asian       PCR-RFLP     HB          Oncology Letter              84    150   37    125   304   103   0.001
  Qi et al.      2014   China     Asian       HRM          PB          BMC cancer                   45    209   60    71    214   121   0.156
  Zhou et al.    2014   China     Asian       PCR-RFLP     HB          Tumor biology                93    139   34    66    160   55    0.018

PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism, PCR-LDR: polymerase chain reaction-ligase detection reaction, MALDI-TOF: matrix assisted laser desorption/ionization-time of flight mass spectrometry, AS-PCR: allele specific-polymerase chain reaction, HRM: high resolution melting, PB: population based studies, HB: hospital based studies, \[\]: published in Chinese, \[Thesis\]: thesis published in Chinese, \[CJPM\]: Chinese Journal of Preventive Medicine, \[CJOPT\]: Chinese Journal of Oncology Prevention and Treatment, APJCP: Asian Pacific Journal of Cancer Prevention, HWE: Hardy--Weinberg equilibrium in control samples, CC1, CT1 and TT1: genotype frequency in cases, CC0, CT0 and TT0: genotype frequency in controls.

###### 

Meta-analysis for the two miRNAs polymorphism and HCC susceptibility.

                                Allele model            Homozygous model   Heterozygote model      Dominant model    Recessive model                                                                                             
  ----------------------------- ----------------------- ------------------ ----------------------- ----------------- ----------------------- ----------------- ----------------------- ----------------- ----------------------- -----------------
  miR-146a rs2910164 (G/C)                                                                                                                                                                                                       
                                G vs C                  GG vs CC           CG vs CC                GG + CG vs CC     GG vs CG + CC                                                                                               
  Overall                       1.06 (0.98, 1.15)       0.124/0.001        1.15 (0.98, 1.36)       0.090/0.003       **1.11 (1.02, 1.21)**   **0.021/0.154**   **1.11 (1.01, 1.22)**   **0.035/0.020**   0.97 (0.86, 1.10)       0.663/0.047
  S1-Caucasian                  0.92 (0.67, 1.27)       0.619/NA           1.05 (0.43, 2.54)       0.920/NA          1.23 (0.49, 3.08)       0.657/NA          1.11 (0.46, 2.66)       0.823/NA          0.86 (0.59, 1.27)       0.452/NA
  S1-Asian                      1.07 (0.99, 1.15)       0.103/0.001        1.15 (0.97, 1.37)       0.097/0.002       **1.11 (1.01, 1.21)**   **0.027/0.119**   **1.11 (1.00, 1.23)**   **0.041/0.014**   0.98 (0.86, 1.12)       0.765/0.037
  S2-HB                         1.02 (0.88, 1.18)       0.772/0.024        1.02 (0.75, 1.39)       0.880/0.032       1.05 (0.89, 1.25)       0.562/0.213       1.05 (0.88, 1.26)       0.597/0.106       0.94 (0.76, 1.17)       0.599/0.273
  S2-PB                         1.09 (1.00, 1.19)       0.062/0.008        **1.25 (1.04, 1.50)**   **0.020/0.024**   **1.14 (1.03, 1.25)**   **0.010/0.214**   **1.15 (1.02, 1.29)**   **0.017/0.047**   0.99 (0.84, 1.16)       0.858/0.024
  S3-HWE_Yes                    **1.10 (1.01, 1.19)**   **0.022/0.011**    1.20 (1.00, 1.43)       0.053/0.005       **1.16 (1.08, 1.26)**   **0.000/0.663**   **1.18 (1.08, 1.28)**   **0.000/0.284**   0.99 (0.86, 1.14)       0.879/0.029
  S3-HWE_No                     0.96 (0.82, 1.14)       0.667/0.057        0.99 (0.66, 1.49)       0.975/0.126       0.96 (0.76, 1.20)       0.702/0.091       0.95 (0.75, 1.22)       0.702/0.042       0.90 (0.68, 1.10)       0.445/0.352
                                                                                                                                                                                                                                 
  miR-196a-2 rs11614913 (C/T)                                                                                                                                                                                                    
                                C vs T                  CC vs TT           TC vs TT                CC + TC vs TT     CC vs TC + TT                                                                                               
  Overall                       **1.14 (1.06, 1.23)**   **0.001/0.009**    **1.31 (1.12, 1.53)**   **0.001/0.006**   1.10 (0.96, 1.25)       0.166/0.006       **1.16 (1.03, 1.31)**   **0.018/0.005**   **1.14 (1.00, 1.30)**   **0.043/0.006**
  S1-Caucasian                  **1.52 (1.13, 2.04)**   **0.006/NA**       **2.41 (1.30, 4.50)**   **0.005/NA**      1.80 (0.99, 3.27)       0.055/NA          **2.04 (1.16, 3.60)**   **0.013/NA**      1.34 (0.87, 2.06)       0.185/NA
  S1-Asian                      **1.12 (1.05, 1.21)**   **0.002/0.021**    **1.28 (1.10, 1.49)**   **0.002/0.014**   1.08 (0.95, 1.22)       0.267/0.009       **1.13 (1.01, 1.28)**   **0.038/0.013**   1.13 (0.99, 1.29)       0.072/0.004
  S2-HB                         1.10 (0.96, 1.28)       0.178/0.005        1.24 (0.92, 1.67)       0.157/0.005       1.06 (0.89, 1.27)       0.488/0.170       1.11 (0.90, 1.38)       0.315/0.026       1.12 (0.95, 1.32)       0.170/0.202
  S2-PB                         **1.16 (1.07, 1.25)**   **0.000/0.176**    **1.36 (1.15, 1.61)**   **0.000/0.139**   1.13 (0.93, 1.38)       0.216/0.003       **1.20 (1.02, 1.41)**   **0.029/0.019**   1.15 (0.94, 1.40)       0.165/0.003
  S3-HWE_Yes                    **1.09 (1.02, 1.18)**   **0.016/0.050**    **1.21 (1.04, 1.40)**   **0.013/0.047**   1.05 (0.91, 1.22)       0.474/0.005       1.10 (0.97, 1.25)       0.138/0.012       1.09 (0.94, 1.26)       0.248/0.007
  S3-HWE_No                     **1.14 (1.06, 1.23)**   **0.000/0.809**    **1.31 (1.12, 1.53)**   **0.000/0.857**   **1.38 (1.05, 1.80)**   **0.019/0.994**   **1.16 (1.03, 1.31)**   **0.001/0.956**   **1.38 (1.12, 1.70)**   **0.003/0.606**

S1: subgroup by ethnicity, S2: subgroup by source of controls, S3: Subgroup by HWE, PB: population based, HB: hospital based, P: P values of association, Ph: P values of heterogeneity, OR: odds ratio, CI: confidence intervals, P \< 0.05 are in bold text.

[^1]: These authors contributed equally to this work.
